Biotech
-
Roche says it’ll move quickly with ‘differentiated’ obesity drugs
CEO Thomas Schinecker claimed the company has “many opportunities” to stand out in the competitive field, and can get to…
Read More » -
Merck claims late-stage study success for RSV antibody
The drug, a rival to Sanofi and AstraZeneca’s fast-selling Beyfortus, met its main goals in a Phase 3 trial. But…
Read More » -
Clinical data registries: Transforming the future of medical research
Clinical data registries have become invaluable for generating unique insights for life sciences. Read on to learn more.
Read More » -
Global tech outage hits US hospitals
At least 11 health systems were experiencing issues Friday after an update by cybersecurity firm CrowdStrike went awry.
Read More » -
Medical device firms have cut more than 14,000 jobs in the past 18 months
Diagnostics is the largest industry represented in the data, with more than 5,000 affected positions, according to an analysis by…
Read More » -
Asceneuron raises another $100M for Alzheimer’s drug development
The Merck KGaA spinout has a tau-regulating medicine it claims could be an “ideal therapy” for Alzheimer’s. The pitch has…
Read More » -
Leqembi sales inch higher; Spark’s pivot leads to layoffs
Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, Ipsen is licensing an ADC and Novartis is…
Read More » -
Pfizer thinks it found its obesity pill
Far behind companies like Novo and Eli Lilly, Pfizer hopes the version of the drug, danuglipron, that it’s chosen to advance can…
Read More » -
FTC criticizes PBM power over prescription drug market
On Tuesday, regulators updated the public on their yearslong probe of PBM's business practices. The report faults PBMs for profiting at the…
Read More » -
CureVac cuts jobs, licenses out vaccines to GSK
The mRNA specialist plans to eliminate 30% of its workforce as part of a restructuring that will prioritize “high-value” projects like…
Read More »